₹722.20
−2.54%NSE close, 16 Nov 2026
+59.30%
Akums Drugs and Pharmaceuticals is a small cap company in the Healthcare sector, listed on NSE under the symbol AKUMS. At ₹722.20 a share, the market values the whole company at ₹11,367 crore.
In FY26, it reported sales of ₹4,359 crore and a net profit of ₹255 crore, an operating margin of 12.0%.
The market values the company at 31.2 times its profit over the last twelve months and 3.25 times its book value; its return on equity is 10.4% and it has almost no borrowings.
Promoters hold 75.26% of the shares. Foreign institutions hold 4.50%, and domestic institutions, mutual funds among them, 11.08%.
Over the past year the share price has risen 56.9%, and it is 13.9% below its 52-week high.
Companies of a similar size in the same sector include Rainbow Childrens Medicare, Concord Biotech, Metropolis Healthcare and Park Medi World.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals | ₹722.20 | ₹11,367 cr | 31.2 | 10.4% | +31.90% | +56.88% |
| Rainbow Childrens Medicare | ₹1,276.80 | ₹12,968 cr | 44.4 | 17.0% | +23.20% | −6.37% |
| Concord Biotech | ₹581.00 | ₹12,156 cr | 43.0 | 13.6% | +25.10% | −17.67% |
| Metropolis Healthcare | ₹574.15 | ₹11,907 cr | 53.1 | 13.7% | +15.80% | +14.50% |
| Park Medi World | ₹245.03 | ₹10,584 cr |
Schedule of meet
Transcript
Link of Recording
Final Report of CRISIL Ratings Limited, Monitoring Agency
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 1,019 | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 | 1,342 |
|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 891 | 912 | 889 | 962 | 895 | 923 | 1,013 | 1,006 | 992 | 1,148 |
| Operating profit | 128 | 121 | 121 | 93.9 | 129 | 94.5 | 147 | 152 | 175 | 195 |
| Operating margin | 12.6% | 11.7% | 12.0% | 8.9% | 12.6% | 9.3% | 12.7% | 13.1% | 15.0% | 14.5% |
| Other income | 6.6 | 13.5 | 14.6 | 17.6 | 26.7 | 32.4 | 34.3 | 35.3 | 30.4 | 28.9 |
| Interest | 13.0 | 11.9 | 5.1 | 4.5 | 23.1 | 23.3 | 23.7 | 23.9 | 24.8 | 25.7 |
| Depreciation | 34.1 | 34.9 | 44.5 | 40.0 | 36.9 | 37.9 | 39.7 | 40.1 | 41.1 | 43.2 |
| Profit before tax | 87.5 | 91.6 | 91.1 | 75.1 | 95.7 | 65.7 | 99.6 | 121 | 139 | 155 |
| Tax | 26.3 | 24.9 | 24.7 | −74.5 | 31.0 | 23.0 | 31.9 | 39.9 | 38.3 | 40.2 |
| Net profit | 60.2 | 65.2 | 65.2 | 148 | 63.5 | 40.8 | 66.3 | 84.6 | 100 | 113 |
| EPS (₹) | 4.21 | 4.37 | 4.26 | 9.64 | 4.15 | 2.66 | 4.33 | 5.53 | 6.53 | 7.37 |
₹ crore, financial years to March.
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|
| From operations | 465 | 1,181 | 256 |
| From investing | −548 | −930 | −354 |
| From financing | 72.8 | 33.9 | −104 |
| Spent on fixed assets | −272 | −231 | −154 |
| Free cash flow | 193 | 951 | 102 |
Margins, returns, debt, tax and cash.
| Line | FY25 | FY26 |
|---|---|---|
| Net margin | 8.2% | 5.9% |
| Operating margin | 11.3% | 12.0% |
| Return on equity | 11.1% | 7.7% |
| Return on capital employed | 12.4% | 14.1% |
| Return on assets | 8.2% | 4.7% |
| Debt to equity | 0.00 | 0.02 |
| Interest coverage | 11.00 | 5.10 |
| Debt to assets | 0.00 | 0.01 |
| Current ratio | 2.55 | 3.25 |
| Quick ratio | 1.78 | 2.56 |
| Cash ratio | 0.11 | 0.35 |
| Asset turnover | 1.00 | 0.80 |
| Fixed asset turnover | 2.96 | 3.01 |
| Inventory turnover | 3.60 | 3.30 |
| Receivables turnover | 5.30 | 5.50 |
| Gross margin | 40.9% | 42.3% |
| Cash from operations to profit | 138.0% | 463.0% |
| Effective tax rate | 0.4% | 32.9% |
| 11.9% |
| n/a |
| n/a |
| Viyash Scientific | ₹236.38 | ₹10,439 cr | 44.9 | 7.3% | +133.00% | +9.21% |
|---|
| Yatharth Hospital & Trauma Care Services | ₹1,069.05 | ₹10,301 cr | 54.9 | 10.0% | +54.40% | +34.65% |
|---|
| Blue Jet Healthcare | ₹512.95 | ₹9,709 cr | 34.0 | 12.4% | +127.10% | −8.67% |
|---|
| Procter & Gamble Health | ₹5,595.50 | ₹9,288 cr | 24.5 | 57.7% | +17.70% | −6.69% |
|---|
Unaudited (standalone & consolidated) financial results for the quarter and half year ended on 30th September, 2026
The financial results for the period ended September 30, 2026.
Schedule of meet
Intimation of ESG Rating
Monitoring Agency Report for the quarter ended June 30, 2026